©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessPOI - Premature Ovarian Insufficiency [replaces POF]

Summary

Short information

Comprehensive differential diagnostic panel for Hyperinsulinism comprising 1 guideline-curated, 16 core candidate and altogether 51 curated genes

ID
PP0200
Number of genes
49 Accredited laboratory test
Examined sequence length
32,3 kb (Core-/Core-canditate-Genes)
99,0 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

Sanger

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GHeredity
AIRE1638AD, AR
BMP151179XL
CLPP834AR
CYP17A11527AR
CYP19A11512AR
EIF2B52166AR
FMR11899XL
FOXL21131AD
FSHB390AR
FSHR2088AR
GALT1140AR
HFM14308AR
MCM82523AR
NOBOX2076AD
NR5A11386AD
PMM2741AR
STAG33678AR
TWNK2055AD, AR
AARS22958AR
BMPR1B1509AD
BUB1B3153AD
C14orf391890AR
DACH21860XL
DIAPH23306XLD
EIF2B41569AR
EIF4ENIF13006AD
FANCM6147AR
FIGLA660AD
GDF91365AD, AR
HARS21521AR
HSD17B42211AR
LARS22712AR
LMNA1995AD
MCM93432AR
MSH42811AR
MSH52505AR
NANOS3593AD
NOG699AD
NUP1072778AR
PGRMC1588XLR
POF1B1770AD
POLG3720AR
POU5F11083AD
PSMC3IP654AR
RCBTB11596AD
SGO23854AR
SOHLH11164AD, AR
SYCE11109AR
SYCP2L2474AR

Informations about the disease

Clinical Comment

Premature or primary ovarian insufficiency (POI) is a clinical syndrome with loss of ovarian activity before the age of 40. POI is characterised by menstrual disorders (amenorrhoea/oligomenorrhoea) with increased gonadotropins and low oestradiol, and has a prevalence of 1%. POI occurs in (pre-)pubescent girls and women from the second decade onwards. The consequences of POI include reduced life expectancy, mainly due to cardiovascular disease and reduced bone density. Negative effects can affect psychological well-being, quality of life and sexuality. Hormone replacement therapy is therefore sometimes indicated after specific problems (Turner syndrome, breast cancer, etc.) have been considered. After karyotype and fragile X-premutation tests, molecular genetic analyses include a number of autosomal and X-linked genes. While 20% of women with fragile X-premutations develop POI, the detection rate in the other genes is lower. Therefore, a normal DNA result does not exclude genetic POI causes.

Reference: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Management-of-premature-ovarian-insufficiency.aspx

 

Synonyms
  • Alias: Follicular stimulating hormone-resistant ovaries
  • Alias: Hypergonadotropic ovarian dysgenesis
  • Alias: Ovarian insufficiency
  • Alias: POI (POF) - premature ovarian insufficiency (failure)
  • Alias: Vorzeitige Ovarialinsuffizienz
  • Alle3lic: Mitochondrial DNA depletion syndrome 7 [hepatocerebral type] (TWNK)
  • Allelic: 46XX sex reversal 4 (NR5A1)
  • Allelic: 46XY sex reversal 3 (NR5A1)
  • Allelic: Acromesomelic dysplasia, Demirhan type (BMPR1B)
  • Allelic: Adrenocortical insufficiency (NR5A1)
  • Allelic: Aromatase excess syndrome (CYP19A1)
  • Allelic: Blepharophimosis, epicanthus inversus + ptosis, type 1 + 2 (FOXL2)
  • Allelic: Brachydactyly, type A1, D + A2 (BMPR1B)
  • Allelic: Brachydactyly, type B2 (NOG)
  • Allelic: Cardiomyopathy, dilated, 1A (LMNA)
  • Allelic: Charcot-Marie-Tooth disease, type 2B1 (LMNA)
  • Allelic: Combined oxidative phosphorylation deficiency 8 (AARS2)
  • Allelic: D-bifunctional protein deficiency (HSD17B4)
  • Allelic: Emery-Dreifuss muscular dystrophy 2, AD (LMNA)
  • Allelic: Emery-Dreifuss muscular dystrophy 3, AR (LMNA)
  • Allelic: Galloway-Mowat syndrome 7 (NUP107)
  • Allelic: Heart-hand syndrome, Slovenian type (LMNA)
  • Allelic: Hutchinson-Gilford progeria (LMNAA)
  • Allelic: Leukoencephalopathy with vanishing white matter (EIF2B5, EIF2B5)
  • Allelic: Leydig cell adenoma, somatic, with precocious puberty (LHCGR)
  • Allelic: Leydig cell hypoplasia with hypergonadotropic hypogonadism (LHCGR)
  • Allelic: Leydig cell hypoplasia with pseudohermaphroditism (LHCGR)
  • Allelic: Lipodystrophy, familial partial, type 2 (LMNA)
  • Allelic: Mandibuloacral dysplasia (LMNA)
  • Allelic: Mitochondrial DNA depletion syndrome 4A {Alpers type] (POLG)
  • Allelic: Mitochondrial DNA depletion syndrome 4B [MNGIE type] (POLG)
  • Allelic: Mitochondrial recessive ataxia syndrome [includes SANDO + SCAE] (POLG)
  • Allelic: Mosaic variegated aneuploidy syndrome 1 (BUB1B)
  • Allelic: Multiple synostoses syndrome 1 (NOG)
  • Allelic: Muscular dystrophy, congenital (LMNA)
  • Allelic: Nephrotic syndrome, type 11 (NUP107)
  • Allelic: Non-obstructive azoospermia (MSH4)
  • Allelic: Ovarian response to FSH stimulation (FSHR)
  • Allelic: Precocious puberty, male (LHCGR)
  • Allelic: Premature chromatid separation trait (BUB1B)
  • Allelic: Progressive external ophthalmoplegia with mitochondrial DNA deletions, AD 3 (TWNK)
  • Allelic: Progressive external ophthalmoplegia, AD 1 (POLG)
  • Allelic: Progressive external ophthalmoplegia, AR 1 (POLG)
  • Allelic: Restrictive dermopathy, lethal (LMNA)
  • Allelic: Spermatogenic failure 1 (SYCE1)
  • Allelic: Spermatogenic failure 32 (SOHLH1)
  • Allelic: Spermatogenic failure 52 (C14orf39)
  • Allelic: Spermatogenic failure 8 (NR5A1)
  • Allelic: Spinal and bulbar muscular atrophy of Kennedy (AR CAG)
  • Allelic: Stapes ankylosis with broad thumbs + toes (NOG)
  • Allelic: Symphalangism, proximal, 1A (NOG)
  • Allelic: Tarsal-carpal coalition syndrome (NOG)
  • 17,20-lyase deficiency, isolated (CYP17A1)
  • 17-alpha-hydroxylase/17,20-lyase deficiency (CYP17A1)
  • Aromatase deficiency (CYP19A1)
  • Autoimmune polyendocrinopathy, type I, with/-out reversible metaphyseal dysplasia (AIRE)
  • Congenital disorder of glycosylation, type Ia (PMM2)
  • Galactosemia (GALT)
  • Hypogonadotropic hypogonadism 24 without anosmia (FSHB)
  • Leukoencephalopathy, progressive, with ovarian failure (AARS2)
  • Luteinizing hormone resistance, female (LHCGR)
  • Malouf syndrome (LMNA)
  • Muscular dystrophy, congenital hearing loss + ovarian insufficiency syndrome (GGPS1)
  • Ovarian dysgenesis 1 (FSHR)
  • Ovarian dysgenesis 2 (BMP15)
  • Ovarian dysgenesis 3 (PSMC3IP)
  • Ovarian dysgenesis 4 (MCM9)
  • Ovarian dysgenesis 5 (SOHLH1)
  • Ovarian dysgenesis 6 (NUP107)
  • Ovarian hyperstimulation syndrome (FSHR)
  • Ovarioleukodystrophy (EIF2B4, EIF2B5)
  • Perrault syndrome 1 (HSD17B4)
  • Perrault syndrome 3 (CLPP)
  • Perrault syndrome 5 (TWNK)
  • Perrault syndrome [panelapp] (SGO2)
  • Premature ovarian failure 1 (POF1; FMR1, 55-200 CCG repeats)
  • Premature ovarian failure 10 (MCM8)
  • Premature ovarian failure 12 (SYCE1)
  • Premature ovarian failure 13 (MSH5)
  • Premature ovarian failure 14 (GDF9)
  • Premature ovarian failure 18 (C14orf39)
  • Premature ovarian failure 2A (DIAPH2)
  • Premature ovarian failure 2B (POF1B)
  • Premature ovarian failure 3 (FOXL2)
  • Premature ovarian failure 4 (BMP15)
  • Premature ovarian failure 5 (NOBOX)
  • Premature ovarian failure 6 (FIGLA)
  • Premature ovarian failure 7 (NR5A1)
  • Premature ovarian failure 8 (STAG3)
  • Premature ovarian failure 9 (HFM1)
  • Premature ovarian failure [panelapp] (BUB1B)
  • Premature ovarian failure [panelapp] (EIF4ENIF1)
  • Premature ovarian insufficiency [panelapp] (BMPR1B)
  • Premature ovarian insufficiency [panelapp] (DACH2)
  • Premature ovarian insufficiency [panelapp] (PGRMC1)
  • Primary ovarian failure [MONDO:0005387] (MSH4)
  • Primary ovarian insufficiency [panelapp] (EIF4ENIF1)
  • Primary ovarian insufficiency [panelapp] (NANOS3)
  • Primary ovarian insufficiency [panelapp] (NOG)
  • Primary ovarian insufficiency [panelapp] (POLR2C)
  • Primary ovarian insufficiency [panelapp] (POLR3H)
  • Primary ovarian insufficiency [panelapp] (POU5F1)
  • Primary ovarian insufficiency [panelapp] (SOHLH2)
  • Primary ovarian insufficiency [panelapp] (SYCP2L)
  • Retinal dystrophy with/-out extraocular anomalies (RCBTB1)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLD
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code
E28.3

Bioinformatics and clinical interpretation

No text defined